|
May 8
|
ChromaDex Corporation Reports First Quarter 2024 Financial Results
|
|
May 6
|
An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 43% Undervalued
|
|
Apr 30
|
ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
|
|
Apr 25
|
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
|
|
Apr 24
|
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
|
|
Apr 23
|
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
|
|
Apr 5
|
Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?
|
|
Apr 2
|
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
|
|
Mar 26
|
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
|
|
Mar 8
|
ChromaDex Full Year 2023 Earnings: EPS Beats Expectations
|
|
Mar 7
|
ChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDA
|
|
Mar 7
|
ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript
|
|
Mar 7
|
Q4 2023 Chromadex Corp Earnings Call
|
|
Mar 6
|
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
|
|
Jan 26
|
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
|
|
Jan 19
|
ChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To Profit
|
|
Dec 20
|
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
|
|
Nov 30
|
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
|
|
Nov 28
|
An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% Undervalued
|
|
Nov 10
|
ChromaDex Corporation (NASDAQ:CDXC) Q3 2023 Earnings Call Transcript
|